Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda

Pediatric Infectious Disease Journal

Volumn 32, Issue 3, 2013, Pages 246-251

  Mutwa, Philippe R ^a,b   Boer, Kimberly R ^b,c   Rusine, John B ^b,d   Muganga, Narcisse ^a   Tuyishimire, Diane ^b,e   Reiss, Peter ^b   Lange, Joep Ma ^b   Geelen, Sibyl P M ^b,f  

^a Centre Hospitalier Universitaire de Kigali   (Rwanda)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ROYAL TROPICAL INSTITUTE   (Netherlands)

^d National Reference Laboratory   (Rwanda)

^e TRAC Plus Center for Treatment and Research on AIDS   (Rwanda)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hepatitis B; HIV infected children and adolescents; Rwanda

Indexed keywords

EFAVIRENZ; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; DIZZINESS; FEMALE; FEVER; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RWANDA; SCHOOL CHILD; SEROLOGY; SORE THROAT; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD; WEAKNESS;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; COHORT STUDIES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; PROSPECTIVE STUDIES; RWANDA;

EID: 84876282101     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318271b93d     Document Type: Article

References (38)

1. Ashir GM, Rabasa AI, Gofama MM, et al. Study of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian children with human immunodeficiency virus infection. Niger J Med. 2009;18:260-262.
2. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhim-bili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health. 2007;7:338.
3. Davis AR, Rosenthal P Hepatitis B in children. Pediatr Rev. 2008;29:111-119; quiz 120.
4. Shepard CW, Finelli L, Fiore AE, et al. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J. 2005;24:755-760.
5. Kourtis AP, Bulterys M, Hu DJ, et al. HIV-HBV coinfection - a global challenge. N EnglJ Med. 2012;366:1749-1752.
6. Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011;31(suppl 1):135-139.
7. Mallet VO, Dhalluin-Venier V, Verkarre V, et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther (Lond). 2007;12:279-283.
8. Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(suppl 1):S65-S70.
9. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49(suppl 5):S138-S145.
10. Lee C, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332:328-336.
11. Rwanda Minisry of Health. Expanded program on immunization, comprehensive multi-year plan 2008-2012.
12. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis. 2004;4:510-518.
13. Abramczuk BM, Mazzola TN, Moreno YM, et al. Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol. 2011;18:1406-1409.
14. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis. 2011;203:984-991.
15. Pessoa SD, Miyamoto M, Ono E, et al. Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART Vaccine. 2010;28:1606-1612.
16. Zuin G, Principi N, Tornaghi R, et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine. 1992;10:857-860.
17. Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41:1045-1048.
18. Kim HN, Harrington RD, Van Rompaey SE, et al. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS. 2008;19:600-604.
19. Abzug MJ, Warshaw M, Rosenblatt HM, et al; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and PI 061s Protocol Teams. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009;200:935-946.
20. Pippi F, Bracciale L, Stolzuoli L, et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med. 2008;9: 519-525.
21. Rwanda Ministy of Health. Guidelines for the provision of comprehensive care to persons infected by HIV in Rwanda 2009.
22. Flynn PM, Cunningham CK, Rudy B, et al; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr. 2011;56:325-332.
23. Rouet F, Chaix ML, Inwoley A, et al; Programme Enfant Yopougon (Agence Nationale de Recherches sur le SIDA et les Hépatites Virales B et C 1244/1278). Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis. 2008;46:361-366.
24. Pirillo MF, Bassani L, Germinario EA, et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol. 2007;79:1797-1801.
25. Hübschen JM, Mugabo J, Peltier CA, et al. Exceptional genetic variability of hepatitis B virus indicates that Rwanda is east of an emerging African genotype E/Al divide. J Med Virol. 2009;81:435-440.
26. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access, version 2010. Available at: http://whqlibdoc.who.int/ publications/2010/9789241599801-eng.pdf Accessed January 7, 2012.
27. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis. 2004;24(suppl 1):31-36.
28. Purdy JB, Gafhi RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152:582-584.
29. Landrum ML, Hullsiek KH, Chun HM, et al. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol. 2011;173:84-93.
30. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine. 2006;24:7124-7128.
31. Lao-araya M, Puthanakit T, Aurpibul L, et al. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine. 2007;25:5324-5329.
32. Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23:2902-2908.
33. Kim HN, Harrington RD, Crane HM, et al. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J S T DAIDS. 2009;20:595-600.
34. Lasheras Lozano ML, Gil Miguel A, Vizcaino Alcaide MJ, et al. Hepatitis B vaccination in children and adolescents. Aten Primaria. 1993;11:286-291.
35. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine. 2009;27:17-22.
36. Potsch DV, Oliveira ML, Ginuino C, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010;28:1447-1450.
37. Psevdos G Jr, Kim JH, Suh JS, et al. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol. 2010;16:1093-1096.
38. Courtney McQueen. FDA Approves Viread For Young HIV-Positive Children. 2012. Available at: http://www.aidsbeacon.com/news/2012/01/19/fda-approves- viread-for-young-hiv-aids-positive-children/. Accessed January 13,2012.